🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to see the 3th paper of a former PhD student ! Compromise for high-dimensional data between sparse model selection and the hierarchical constraint with penalised biomarker x treatment interactions... CESP GS Santé Publique Gustave Roussy bmcbioinformatics.biomedcentral.com/articles/10.11…

Cherry on the pie of a great PhD of Claire Petit, MD with important clinical implications for nasopharynx carcinoma CESP GS Santé Publique in Oncostat team labeled La Ligue contre le cancer

And another paper from the Oncostat team in the same The Lancet Oncology issue with Arnaud Bayle on the variability of HTA assessments CESP GS Santé Publique

Happy to be part of this huge project by TG9 of The STRATOS initiative led by J. Rahnenführer, L McShane and @RiccardoDeBin1, with Stefan Michiels Lara and others

Celebrating 40years of the landmark Early Breast Cancer Trialists' Collaborative Group in Oxford with a hommage to the former Gustave Roussy director Gustave Roussy @GroupeUnicancer FabriceAndre Fabrice Barlesi Pascale Flamant

⭐️Super honored to chair the most important session (in my opinion) in ESMO - Eur. Oncology #MAP23 “What are regulatory road blocks in #Tumor agnostic drug development”. 👉🏼Had a great time moderating FDA, EMA, Patient advocacy & Biostatistics perspectives. ⭐️All for faster patient access to

Great Pdh work by Valentine Grumberg supervised by Prof Borget on estimating clinical benefit of immunotherapies in advanced cancers in France in 2014-21 CESP #Oncostat Gustave Roussy

Finally the long awaited results of the meta-analysis of anti-EGFR in locally advanced head neck cancer by Pierre Blanchard, MD CESP Gustave Roussy #Oncostat #ESMO2023

Confidence intervals for expected survival probabilities obtained from neural networks - happy to see this paper out of joint PhD student with MICS CentraleSupélec and Oncostat CESP Gustave Roussy Université Paris-Saclay sciencedirect.com/science/articl…

Metastatic cancers should be classified as much as possible based on their biology, and agnostic of organ of origin To reach this vision, new statistical tools are needed to claim that drugs work across multiple cancers TY nature & Lucy Odling-Smee for the opportunity to write about it

International collobaration can pull randomised clinical trials off even in ultra-rare diseases in cancer, with stats and data manag Gustave Roussy thelancet.com/journals/lance…

thanks for the great session European Breast Cancer Conference (EBCC-15) EORTC Breast Cancer Group

Finally our internat meta-analytical study of the prognostic role of tumour infiltrating lymphocytes in TNBC not treated with chemo is out ! CESP #breastcancer

Thanks to the #ESMOBreast24 conference organizers for allowing us to discuss important clinical trial design challenges in breast cancer ! ESMO - Eur. Oncology #bcsm Sara Tolaney Tatiana Prowell, MD Tomás Pascual Erika Hamilton, MD

👏 to Léa Orsini for a 🏅 student award at the 45th Intern Society for Clinical Biostatistics meeting - #PhD in #Oncostat CESP ISCB45 ISCB_info Gustave Roussy Université Paris-Saclay GS Santé Publique #Thessaloniki #ISCB45 #clinicaltrials #survivalanalysis #bayesian #ISCB2024

great to have the results out of our academic Gustave Roussy randomized trial in leiomyosarcoma with French Sarcoma Group #rarecancer #RCT